Key Highlights
- $25M Series A funding led by B Capital, joined by CVS Health Ventures, CommonSpirit Health, and others.
- Innovative AI-driven platform enhances diagnosis, treatment, and caregiver support for neurodegenerative diseases.
- Focus on expanding partnerships, scaling operations, and increasing access to clinical trials across the U.S.
Source: Direct
Notable Quotes
- “This investment will enable Synapticure to continue to democratize care for people and their families living with neurodegenerative diseases.” — Sandra Abrevaya, CEO at Synapticure
- “Synapticure’s mission aligns closely with our focus on investing in transformative healthcare companies led by visionary founders.” — Adam Seabrook, Partner at B Capital
- “We believe we go farther, faster when we work with partners who champion new models of care.” — Anuradhika A., System VP at CommonSpirit Health
SoHC's Take
Synapticure’s $25 million Series A funding marks a critical step forward in addressing the challenges faced by millions of patients and caregivers managing neurodegenerative diseases. The company’s focus on leveraging AI-powered analytics, expanding access to clinical trials, and partnering with healthcare systems positions it as a transformative force in virtual care. This funding not only underscores investor confidence in Synapticure’s mission but also highlights the growing demand for innovative, patient-centered care solutions in an aging population. By delivering quicker access to specialized care and supporting groundbreaking clinical research, Synapticure is setting a new standard for holistic, accessible healthcare in the neurodegenerative space.
